Drug Profile


Alternative Names: NXL-103; RPR 202868/RPR 132552; XRP 2868

Latest Information Update: 06 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer AstraZeneca
  • Class Antibacterials; Streptogramins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Community-acquired pneumonia; Skin and soft tissue infections

Most Recent Events

  • 03 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in Ukraine, Romania, Poland, Estonia, Peru, Croatia, Germany, South Africa and Chile (PO)
  • 03 Sep 2015 No recent reports on development identified - Phase-II for Skin and soft tissue infections in Guatemala and USA (PO)
  • 06 Nov 2009 Phase-II clinical trials in Skin and soft tissue infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top